×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZIA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
09:00 am
kzia
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Medium
Report
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
11/18
04:56 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
11/18
04:15 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
10/30
05:31 pm
kzia
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
Medium
Report
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
10/30
05:31 pm
kzia
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
Medium
Report
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
10/27
07:15 am
kzia
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Low
Report
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
10/14
05:31 pm
kzia
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
10/14
05:31 pm
kzia
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/5
04:06 pm
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 05
Neutral
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 05
12/2
04:06 pm
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 02
High
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Dec 02
11/18
04:20 pm
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Medium
Report
Form 424B3 KAZIA THERAPEUTICS LTD
11/18
04:19 pm
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Medium
Report
Form 424B3 KAZIA THERAPEUTICS LTD
11/18
04:18 pm
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
Medium
Report
Form 424B3 KAZIA THERAPEUTICS LTD
11/18
04:15 pm
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Nov 18
High
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Nov 18
11/14
12:48 pm
kzia
Form SCHEDULE 13G/A KAZIA THERAPEUTICS LTD Filed by: Dauntless Investment Group, LLC
Medium
Report
Form SCHEDULE 13G/A KAZIA THERAPEUTICS LTD Filed by: Dauntless Investment Group, LLC
11/7
04:02 pm
kzia
Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30
Low
Report
Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/8
New positive data from phase IIa trial in brain cancer patients
12.8%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
TOP News Decliners
11/20
Kazia Therapeutics up 83% [Seeking Alpha]
-18.9%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: